

## Revolution in Oncology : Transforming Minimally Invasive Treatment for Solid Tumors

Ilan Uchitel

Company name CAPS Medical

\* Website [www.capsmedical.com](http://www.capsmedical.com)

CEO name Ilan Uchitel

CATEGORY: Medical Devices

SESSIONS • Is it time to celebrate the rebound of the medical device sector? • Evolving trends in cancer therapeutics

o Executive Summary CAPS Medical NTAP™ system targets the \$100B oncology market and aims to selectively and precisely destroy only solid tumors while sparing healthy tissue in a minimally invasive procedure. The company successfully completed clinical study for it's first indication - bladder cancer, after which it will be extended to wide range of solid tumors found in lung, liver, and other cancers.

o Core Technology NTAP™ is a highly selective and minimally invasive Non-thermal Plasma platform designed to painlessly treat a wide range of solid tumors without impacting surrounding tissue. Overcoming the limitation of existing technologies now, for the first time NTAP can selectively target and destroy cancerous solid tumors in internal organs by making use of existing, keyhole minimally invasive procedures to avoid surgery.

o Product Profile/Pipeline The company is now conducting first clinical study that focuses on non-muscle invasive bladder cancer (NMIBC). More than 1.6M patients suffering from the disease worldwide, with 2000,000 new cases annually. CAPS is working to expand the treatment options for additional indications, such as cancers of the lung, liver, pancreas and others, collaborating with medical robotic companies.

o Business Strategy Targeting FDA approval for Bladder Cancer. The NTAP technology will replace operation room with simple in-office procedure. Console and consumable business model with revenues mostly driven by the consumable NTAP™ procedure kit (one per procedure) with a high margin of >90%. The consoles will be sold directly to hospitals and clinics, resold to distributors and leased.

o What's Next? Pivotal clinical studies towards marketing clearance for it's initial indication. The progress achieved by the company allows it to scale and accelerate the development of the NTAP™ system and the clinical program to enable the use of the technology for additional indications. The company in process of raising "B" Series funding to support it's rapid growth.